Our data suggests that TFAP2C and PELP1 signaling plays a role in ER+ BC progression and that the PELP1 dysregulation, commonly seen in breast tumors, may contribute to enhanced TFAP2C oncogenic signaling. This evidence concerns the gene TFAP2C and breast neoplasm.